EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • August 7th, 2015 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research • New York
This Exclusive License Agreement (this “Agreement”), dated as of April 21, 2015 (the “Effective Date”), is entered into by and between NantCell, Inc., formerly NantBioCell, LLC and NantCell, LLC (“NantCell”), a Delaware limited liability company, and Sorrento Therapeutics, Inc. (“Sorrento”), a Delaware corporation. NantCell and Sorrento are each sometimes referred to herein as a “Party” and collectively as the “Parties.” Capitalized terms used and not otherwise defined herein have the meaning set forth on Exhibit B attached hereto.
STOCK SALE AND PURCHASE AGREEMENTStock Sale and Purchase Agreement • August 7th, 2015 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research • New York
This STOCK SALE AND PURCHASE AGREEMENT (including the exhibits hereto, this “Agreement”), dated as of May 14, 2015 (the “Execution Date”), is entered into by and between NantPharma, LLC, a Delaware limited liability company (“Purchaser”), and Sorrento Therapeutics, Inc., a Delaware corporation (“Seller”). Capitalized terms used and not otherwise defined in this Agreement have the meanings set forth in Exhibit A.
